Delving into the Latest Updates on Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) with Synapse

Overview

Basic Info

Drug Type

TIL therapy

Synonyms

CD40L TIL(H. Lee Moffitt Cancer Center and Research Institute)

Target

CD40L

Action

stimulants

Mechanism

CD40L stimulants(CD40 ligand stimulants), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsRespiratory DiseasesUrogenital Diseases

Active Indication

Non-Muscle Invasive Bladder NeoplasmsUrothelial Carcinoma of the Urinary BladderAdvanced Lung Non-Small Cell Carcinoma+ [2]

Inactive Indication

Melanoma, Cutaneous MalignantMetastatic melanoma

Originator Organization

H. Lee Moffitt Cancer Center & Research Institute, Inc.

Active Organization

H. Lee Moffitt Cancer Center & Research Institute, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

Start Date11 Oct 2017

Sponsor / Collaborator

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+4]

100 Clinical Results associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

100 Translational Medicine associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

100 Patents (Medical) associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

100 Deals associated with Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Muscle Invasive Bladder Neoplasms	Phase 1	United States	H. Lee Moffitt Cancer Center & Research Institute, Inc.	10 Aug 2023
Urothelial Carcinoma of the Urinary Bladder	Phase 1	United States	H. Lee Moffitt Cancer Center & Research Institute, Inc.	10 Aug 2023
Advanced Lung Non-Small Cell Carcinoma	Phase 1	United States	H. Lee Moffitt Cancer Center & Research Institute, Inc.	10 Mar 2023
metastatic non-small cell lung cancer	Phase 1	United States	H. Lee Moffitt Cancer Center & Research Institute, Inc.	10 Mar 2023
Recurrent Non-Small Cell Lung Cancer	Phase 1	United States	H. Lee Moffitt Cancer Center & Research Institute, Inc.	10 Mar 2023
Melanoma, Cutaneous Malignant	Phase 1	United States	H. Lee Moffitt Cancer Center & Research Institute, Inc.	08 Mar 2016
Metastatic melanoma	Phase 1	United States	H. Lee Moffitt Cancer Center & Research Institute, Inc.	08 Mar 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2024	Not Applicable	Unresectable Melanoma	102	Tumor Infiltrating Lymphocytes (TIL)	exfhgsljsp(awceozhldb) = ICI-related toxicity was identified in 22 patients (24%), and among those 6 patients (27%) had a recurrence of a toxicity seen with pre-TIL ICI jkgkdigdee (uashqdmxud ) View more	Negative	14 Sep 2024
ESMO2024	Not Applicable	Unresectable Melanoma	102	Immune Checkpoint Inhibitor (ICI) Rechallenge		Negative	14 Sep 2024
ASCO2014	Phase 2	Metastatic melanoma	56	Tumor-infiltrating lymphocytes (TIL)	yttmwqjdlh(rmplrxxcvi) = jcbskdtnfx nyanpcsefs (aybngznycj )	Positive	20 May 2014